Many variables in trying to value a immuno-oncology drug.
Below based on US Bio research specialist. A rough guide only.
Start of each phase - oncology single molecule valuation estimation ($US)
Phase 1 $105M - Probability of FDA approval: 12%
Phase 2 $285m - probability of FDA approval: 20%
Phase 3 $1,248m - probability of FDA approval: 56%
Completion phase 3 - FDA submission - $3,500m
FDA approved and commercialisation - $4,500m+
Above could be multiplied by x% based on multiple indications.
So, what's Efti worth right now?
Ann: Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma, page-8
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $480.0M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.5¢ | 32.0¢ | $1.703M | 5.215M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 211685 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 279000 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |